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ABSTRACT 
Introduction 
Calcium channel blockers (CCBs) may affect prostate cancer (PCa) growth by modulating calcium-
regulated tumorigenic processes. Recent epidemiological data showed etiological differences by 
molecular subtypes of PCa, in particular for PCa with the TMPRSS2:ERG (T2E) gene fusion. We studied 
the association between CCB use and risk of PCa overall and stratified by T2E status.  
Methods 
Participants were residents of King County, Washington, recruited for population-based case─control 
studies (1993─1996 or 2002─2005). Tumor T2E status was determined by fluorescence in situ 
hybridization using tumor tissue samples from radical prostatectomy specimens. Detailed information 
on use of CCBs and other variables was obtained through in-person interviews. Binomial and 
polytomous logistic regression were used to generate odds ratios (ORs) and 95% confidence intervals 
(CIs). 
Results 
The study includes 1,747 PCa patients and 1,635 age-matched controls. A subset of 563 radical 
prostatectomy patients had T2E status determined, of which 295 were T2E positive (52%). Use of CCBs 
(ever vs. never) was not associated with overall PCa risk. However, among European-American men, 
users had a reduced risk of higher-grade PCa (Gleason scores ≥7: adjusted OR = 0.64; 95% CI: 0.44, 0.95). 
Further, use of CCBs was associated with a reduced risk of T2E positive PCa (adjusted OR = 0.38; 95% CI: 
0.19, 0.78), but not T2E negative PCa. 
Conclusion 
Use of CCBs was associated with reduced relative risks for higher Gleason score and T2E positive PCa. 
Future studies of PCa etiology should consider etiologic heterogeneity as PCa subtypes may have 
different causal pathways.  
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INTRODUCTION 
Prostate cancer (PCa) is the most frequently diagnosed solid tumor in men (1). There is substantial 
heterogeneity among primary prostate cancers, evident in the spectrum of its molecular alterations and 
patients’ variable prognosis (2). One of the most common somatic alterations in PCa is the gene fusion 
TMPRSS2:ERG (T2E), which is an early event in PCa that occurs in about half of all patients of European 
ancestry (3,4). There is substantial evidence that T2E positive PCa represents a distinct disease subtype 
with different underlying oncogenic pathways (2,5-8). Several recent epidemiological studies also 
showed etiological differences by T2E status identifying specific risk factors that were uniquely 
associated with T2E positive but not T2E negative disease (9-11). 
Calcium channel blockers (CCBs) are used for the treatment of hypertension (12). Frequently prescribed 
CCBs include dihydropyridines (e.g., nifedipine), phenylalkylamines (e.g., verapamil), and 
benzothiazepines (e.g., diltiazem) (13,14). These drugs target calcium channels, which regulate calcium 
homeostasis (15,16), and may thereby alter cellular processes relevant to cancer including proliferation 
and apoptosis (16-18). Increased calcium channel activity has been associated with increased cellular 
proliferation and cancer growth (19,20). Many studies have identified alterations in the expression of 
calcium channel genes in cancer, including PCa (16,19,21). Different types of calcium channels have 
been implicated in prostate carcinogenesis including members of the ORAI, TRP, L-type and T-type 
family of channels (19,22-25). Further, there is some evidence of calcium channel genes being 
differentially expressed in prostate tumors that harbor the T2E fusion (5,8,22,26-28). 
A number of prior epidemiological studies have investigated the association of CCB use with PCa risk 
(29). Two of the studies reported an inverse association (30,31), six studies found no evidence of an 
association (32-37), and one study showed a positive association (38). These prior studies, however, did 
not comprehensively investigate the association of CCB use with features of more aggressive PCa; and 
no prior study has examined the association stratified by molecular subtypes of PCa such as T2E gene 
fusion-positive disease. 
In the present population-based study we investigated associations between CCB use and PCa risk. We 
examined associations with risk of overall and more aggressive PCa, and in men with T2E positive and 
T2E negative PCa.  
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METHODS 
Study population 
Study participants were residents of King County, Washington, who participated in population-based 
case─control studies (39,40). Incident cases diagnosed with histologically confirmed adenocarcinoma of 
the prostate were identified via the Seattle-Puget Sound Surveillance, Epidemiology, and End Results 
cancer registry. Cases from the first study (ages: 40 to 64 years) were diagnosed with PCa from 1993 
through 1996 and cases from the second study (ages: 35 to 74 years) were diagnosed between 2002 and 
2005. In total, 1,754 patients were available for the study. Data on Gleason score, diagnostic prostate-
specific antigen (PSA) level, and tumor stage were collected from the cancer registry. Population-based 
controls without a history of PCa (n = 1,645) were identified using random digit telephone dialing, 
recruited evenly throughout the ascertainment periods for cases, and frequency-matched to cases by 
five-year age groups. All participants signed informed consent for participation, and the studies were 
approved by the Fred Hutchinson Cancer Research Center Institutional Review Board. 
Use of calcium channel blockers 
Information on lifetime use of CCBs was obtained during a detailed in-person interview. Medication 
show cards were used to obtain information on the type of CCB used. Seven cases and ten controls had 
missing data on CCB use and were excluded from the analysis. In addition, data on duration of use, time 
of first use, and current vs. former use were available for the subset of men in the second study, but not 
the men in the first study. Information on several other factors including demographic and lifestyle 
factors, personal and family medical history, and other cancer-related factors was collected during the 
interview.  
Determination of TMPRSS2:ERG gene fusion status 
Formalin-fixed, paraffin-embedded tumor tissue blocks from radical prostatectomy specimens were 
used to make hematoxylin and eosin stained slides. These slides were reviewed by a prostate 
pathologist, who marked areas containing ≥75% tumor tissue. From these areas, two 1-mm tumor cores 
were taken and embedded in recipient paraffin blocks for the creation of tumor tissue microarrays. 
Fluorescence in situ hybridization (FISH) ‘break-apart’ assays were used to determine T2E status. A two-
color FISH technique was used as described previously (9). In total, 563 patients had T2E status available 
for analysis. 
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Statistical data analysis 
Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the 
association between ever vs. never use of CCBs and PCa risk. Polytomous logistic regression was used for 
the analysis in which patients were stratified by tumor T2E status and Gleason score (<7 vs. ≥7). The 
statistical models were adjusted for age (five-year age groups) and race (African-American, European-
American). Other variables were also considered as potential confounders: education, body mass index, 
lifetime alcohol consumption, aspirin and other NSAIDs use, recent exercise frequency, history of 
diabetes mellitus, and history of hypertension. We investigated the effect of adding these variables to 
the model, one by one, on the OR for CCB use. Only body mass index (continuous) and history of 
hypertension (no, yes) changed the OR by at least 5%; and these variables were therefore additionally 
included in the final model. Associations were also evaluated in the subgroup of European-American 
men. African-American patients were not considered separately because the numbers were too small. 
All P-values were two-sided and a P-value of less than 0.05 was considered to be statistically significant. 
All statistical analyses were conducted using the R programming language.  
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RESULTS 
The study population included 1,747 PCa patients and 1,635 controls (Table 1). As expected, patients 
were more likely to have a first-degree family history of PCa compared to controls. Tumor tissue was 
collected for the patients who had a radical prostatectomy as their primary treatment for PCa, which 
was used to determine T2E status. Of the 563 patients with T2E data, 295 (52%) had tumors that were 
T2E gene fusion-positive. Positive fusion status was associated with younger ages at diagnosis and 
European-American ancestry. Patients with T2E positive tumors had lower Gleason scores. Almost all 
CCB users in the study used drugs from the following drug classes: dihydropyridines (52.9%), 
phenylalkylamines (24.8%), and benzothiazepines (21.8%).  
The frequency of any CCB use among controls was 8.6% (Table 2). Use of CCBs was not associated with 
the relative risk of overall, lower-grade (Gleason <7), or higher-grade (Gleason ≥7) PCa with adjusted 
ORs of 0.87 (95% CI: 0.67, 1.13), 0.99 (95% CI: 0.73, 1.33), and 0.74 (95% CI: 0.53, 1.04), respectively 
(Table 2). However, in the subgroup of European-American men, use of CCBs was inversely associated 
with risk of higher-grade PCa (adjusted OR = 0.64; 95% CI: 0.44, 0.95). The association was more 
pronounced for Gleason ≥7(4+3) PCa revealing an adjusted OR of 0.53 (95% CI: 0.29, 0.98). There was no 
evidence suggesting that the associations differ substantially by type of CCB. For a subset of men, data 
were available on current vs. former use, duration of use, and time since first use of CCBs. No significant 
associations were found in these subgroups (Table 3). In the subgroup of European-American men, 
however, current use of CCBs was associated with a lower risk of higher-grade PCa (adjusted OR = 0.44, 
95% CI: 0.23, 0.83). 
Table 4 shows the association between CCB use and PCa risk stratified by T2E status. Use of CCBs was 
associated with a reduced risk of T2E positive PCa with an adjusted OR of 0.38 (95% CI: 0.19, 0.78). Of 
the T2E positive PCa patients that were CCB users, 78% (7 out of 9) had lower-grade disease (Gleason 
scores ≤6). No association was observed for T2E negative PCa (adjusted OR = 1.05; 95% CI: 0.65, 1.69). 
The association of CCB use with fusion-positive PCa was slightly more pronounced when the analysis 
was restricted to European-American men (adjusted OR = 0.33; 95% CI: 0.15, 0.73). Among the subset of 
European-American men, all T2E positive PCa patients who used CCBs (n = 7) had lower-grade disease 
(Gleason scores ≤6).  
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DISCUSSION 
This PCa case─control study showed that ever use of CCBs was associated with a decreased risk in 
patients whose tumors were positive for the T2E gene fusion, which is an important molecular subtype 
of PCa. No associations were observed between CCB use and risk of T2E negative PCa. In the larger study 
population there was no association between CCB use and overall PCa risk, however, among European-
American men CCB use was inversely associated with risk of higher-grade PCa. 
Although prior studies have not investigated the association between CCB use and PCa risk in patients 
stratified by tumor T2E status; at least nine observational studies of CCBs and overall PCa risk have been 
conducted (29,32,37). Of these, two small prospective studies found an inverse association. The first 
study by Fitzpatrick et al. included 2,442 men (151 PCa patients), and found that CCB users had a relative 
risk of PCa of 0.6 (95% CI: 0.4, 0.9) (30). The second study by Debes et al. included 1,362 men (135 PCa 
patients), and showed that CCB users had a relative risk of PCa of 0.55 (95% CI: 0.31, 0.97) (31). The 
majority of studies, however, found no association between CCB use and PCa risk. These investigations 
include three cohort studies (2 prospective and 1 retrospective study) (32,34,37), including a prospective 
cohort study with 3,031 incident PCa patients (34), and four case─control studies (33,35,36,38). Only 
one previous observational study specifically investigated CCB use in relation to more aggressive PCa 
features, and the study found no association (34). Based on our results showing an inverse association 
between CCB use and higher-grade PCa, further studies are needed to examine whether CCBs might be 
associated with a reduced risk of more clinically aggressive forms of PCa. Our study also showed novel 
evidence that CCBs may reduce the risk of T2E positive PCa. Given that this is the first study to examine 
the association; further molecular epidemiological studies focused on CCB use in patients stratified by 
T2E tumor subtypes are needed. 
Calcium channels regulate calcium homeostasis and are involved in several important cellular 
mechanisms (16,19). Altered expression of calcium channel genes is common in cancer, and increased 
calcium channel activity can increase cellular proliferation and may promote PCa growth (21). 
Overexpression of specific calcium channels genes may also protect PCa cells from apoptosis (23,41). 
Although the precise biological mechanisms through which CCBs may reduce risk of T2E positive PCa are 
unclear, one possible mechanism might involve the calcium channel gene CACNA1D, which is known to 
be highly overexpressed in T2E positive PCa (5,8,22,26-28). Previous evidence from our group showed 
that this increase in CACNA1D expression may result from aberrant tumor DNA methylation of the gene 
(8). CACNA1D encodes the calcium-channel, voltage-dependent, L-type, alpha 1D subunit, Cav1.3 (42). 
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This L-type calcium channel is a target of the most commonly prescribed CCBs including 
dihydropyridines, phenylalkylamines, and benzothiazepines (13,14). Further, it has been shown that 
suppression of CACNA1D inhibits androgen-stimulated calcium influx, androgen receptor 
transactivation, and PCa cell growth (22). Additional mechanistic studies are needed to fully understand 
the potential link between use of CCBs and development of T2E positive tumors, and the potential 
involvement of the CACNA1D gene. 
Strengths of this study include its population-based design, availability of data on many potential 
confounding variables, and data on tumor T2E gene fusion status determined using fluorescence in situ 
hybridization, which is considered the ‘gold standard’ for assessing the gene fusion. Because of the 
retrospective study design, the possibility of recall bias in relation to medication use cannot be ruled 
out. However, we would not expect recall to vary by tumor molecular subtype, which is therefore 
unlikely to have impacted our findings related to T2E status. Another potential limitation is that tumor 
T2E status was only available for the subset of patients who chose radical prostatectomy for primary 
treatment. Finally, although we adjusted for many potential confounders, residual confounding might be 
a problem. For example, use of CCBs is clearly a marker for the presence of high blood pressure, which is 
linked to obesity and cardio-metabolic abnormalities that may increase cancer incidence. That would, 
however, not explain the reduced relative risk observed in our study. 
In conclusion, the present study showed that CCB use was associated with a lower risk of an important 
molecular subtype of PCa, T2E gene fusion-positive disease. If confirmed, our results suggest that CCBs, 
which are commonly used for the treatment of hypertension, may also reduce the risk of developing T2E 
positive PCa, a molecular subtype of PCa that represents approximately half of all prostate tumors 
diagnosed in men of European ancestry. This molecular epidemiological study of PCa highlights the 
importance of examining molecular subtypes when studying cancer risk or protective factors.  
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Table 1 
Characteristics of study participants, King County, WA, 1993–1996 and 2002–2005. 
  Controls    Overall PCa cases  T2E negative PCa cases T2E positive PCa cases 
  (n = 1,635)  (n = 1,747)  (n = 268)   (n = 295)   
Variables  Mean (SD) No. % Mean (SD) No. % Mean (SD) No. % Mean (SD) No. % 
Age (years) 59.2 (7.2) ─ ─ 59.8 (7.0) ─ ─ 59.3 (6.9) ─ ─ 56.9 (6.6) ─ ─ 
Race              
 African-American ─ 114 7.0% ─ 205 11.7% ─ 30 11.2% ─ 15 5.1% 
 European-American ─ 1,521 93.0% ─ 1,542 88.3% ─ 238 88.8% ─ 280 94.9% 
              
First-degree family history of PCa           
 No ─ 1,457 89.1% ─ 1,381 79.0% ─ 204 76.1% ─ 232 78.6% 
 Yes ─ 178 10.9% ─ 366 21.0% ─ 64 23.9% ─ 63 21.4% 
Body mass index (kg/m2) 27.2 (4.2) ─ ─ 27.1 (4.1) ─ ─ 26.9 (3.7) ─ ─ 26.7 (3.7) ─ ─ 
Smoking status             
 Never ─ 690 42.2% ─ 705 40.4% ─ 112 41.8% ─ 128 43.4% 
 Former ─ 713 43.6% ─ 808 46.3% ─ 133 49.6% ─ 135 45.8% 
 Current ─ 232 14.2% ─ 234 13.4% ─ 23 8.6% ─ 32 10.9% 
History of hypertension            
 No ─ 1,125 68.9% ─ 1,122 64.2% ─ 175 65.3% ─ 206 69.8% 
 Yes ─ 508 31.1% ─ 625 35.8% ─ 93 34.7% ─ 89 30.2% 
Gleason score             
 ≤6 ─ ─ ─ ─ 983 56.5% ─ 117 43.7% ─ 161 54.6% 
 7(3+4) ─ ─ ─ ─ 478 27.5% ─ 96 35.8% ─ 100 33.9% 
 7(4+3) ─ ─ ─ ─ 113 6.5% ─ 32 11.9% ─ 15 5.1% 
 8─10 ─ ─ ─ ─ 165 9.5% ─ 23 8.6% ─ 19 6.4% 
Disease stage             
 Local ─ ─ ─ ─ 1,366 78.2% ─ 186 69.4% ─ 200 67.8% 
 Regional ─ ─ ─ ─ 334 19.1% ─ 81 30.2% ─ 95 32.2% 
 Distant ─ ─ ─ ─ 47 2.7% ─ 1 0.4% ─ 0 0.0% 
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PSA (ng/mL) at diagnosis            
 <4 ─ ─ ─ ─ 227 14.1% ─ 33 13.2% ─ 54 19.4% 
 4─<10 ─ ─ ─ ─ 970 60.2% ─ 156 62.2% ─ 176 63.3% 
 10─<20 ─ ─ ─ ─ 250 15.5% ─ 45 17.9% ─ 31 11.2% 
 ≥20 ─ ─ ─ ─ 163 10.1% ─ 17 6.8% ─ 17 6.1% 
Primary treatment             
 Radical prostatectomy ─ ─ ─ ─ 984 56.1% ─ 268 100.0% ─ 295 100.0% 
 Radiation with or without ADT ─ ─ ─ ─ 508 29.0% ─ ─ ─ ─ ─ ─ 
 ADT only ─ ─ ─ ─ 91 5.2% ─ ─ ─ ─ ─ ─ 
 Active surveillance ─ ─ ─ ─ 164 9.4% ─ ─ ─ ─ ─ ─ 
 Other ─ ─ ─ ─ 7 0.4% ─ ─ ─ ─ ─ ─ 
Note: ADT: androgen-deprivation therapy; PCa, prostate cancer; PSA, prostate-specific antigen; SD, standard deviation; T2E, TMPRSS2:ERG.  
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Table 2 
Associations between calcium channel blocker use and risk of overall, lower-grade, and higher-grade 
prostate cancer, King County, WA, 1993–1996 and 2002–2005. 
   Calcium channel blocker use 
   No Yes  
   OR (ref) OR (95% CI) 
All men     
  No. controls 1,495 140  
 Overall PCa    
  No. cases 1,598 149  
  Age-adjusted 1.00 0.97 (0.76, 1.24) 
  Multivariable-adjusted
a 1.00 0.87 (0.67, 1.13) 
 Gleason score <7    
  No. cases 896 87  
  Age-adjusted 1.00 1.05 (0.79, 1.39) 
  Multivariable-adjusted
a 1.00 0.99 (0.73, 1.33) 
 Gleason score ≥7    
  No. cases 695 61  
  Age-adjusted 1.00 0.78 (0.57, 1.08) 
  Multivariable-adjusted
a 1.00 0.74 (0.53, 1.04) 
      
European-American men    
  No. controls 1,397 124  
 Overall PCa    
  No. cases 1,426 116  
  Age-adjusted 1.00 0.91 (0.70, 1.19) 
  Multivariable-adjusted
a 1.00 0.84 (0.63, 1.12) 
 Gleason score <7    
  No. cases 810 75  
  Age-adjusted 1.00 1.08 (0.80, 1.46) 
  Multivariable-adjusted
a 1.00 1.00 (0.72, 1.38) 
 Gleason score ≥7    
  No. cases 611 40  
  Age-adjusted 1.00 0.69 (0.48, 1.00) 
  Multivariable-adjusted
a 1.00 0.64 (0.44, 0.95) 
Note: CI, confidence interval; OR, odds ratio; PCa, prostate cancer. 
a Models were adjusted for age (five-year age groups), race (African-American, European-American), 
body mass index (continuous), and history of hypertension (no, yes).  
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Table 3 
Odds ratio and 95% confidence interval for prostate cancer risk by categories of calcium channel blocker 
use, King County, WA, 2002–2005a. 
   All men     European-American men  
   No. controls No. cases OR (95% CI)  No. controls No. cases OR (95% CI) 
Overall PCa          
 Use           
  Never (ref.) 844 901 1.00   757 768 1.00  
  Former 31 35 1.00 (0.60, 1.66)  29 31 1.00 (0.59, 1.70) 
  Current 67 65 0.82 (0.56, 1.19)  58 44 0.71 (0.47, 1.09) 
 Duration of use, years        
  <5 37 41 0.97 (0.61, 1.56)  31 34 1.02 (0.61, 1.70) 
  ≥5 54 56 0.87 (0.58, 1.31)  49 38 0.73 (0.47, 1.15) 
 Time since first use, years         
  <5 28 27 0.84 (0.48, 1.45)  23 23 0.93 (0.51, 1.69) 
  ≥5 60 67 0.94 (0.64, 1.38)  56 46 0.76 (0.51, 1.17) 
            
Gleason score <7         
 Use           
  Never (ref.) 844 469    757 407 1.00  
  Former 31 18 1.03 (0.56, 1.89)  29 15 0.94 (0.49, 1.81) 
  Current 67 38 0.99 (0.64, 1.53)  58 30 0.93 (0.58, 1.51) 
 Duration of use, years        
  <5 37 27 1.27 (0.75, 2.15)  31 23 1.32 (0.74, 2.34) 
  ≥5 54 27 0.88 (0.54, 1.45)  49 20 0.75 (0.43, 1.31) 
 Time since first use, years         
  <5 28 19 1.18 (0.64, 2.16)  23 17 1.32 (0.69, 2.55) 
  ≥5 60 35 1.03 (0.66, 1.63)  56 26 0.84 (0.51, 1.40) 
            
Gleason score ≥7         
 Use           
  Never (ref.) 844 428    757 359 1.00  
  Former 31 17 0.99 (0.53, 1.84)  29 16 1.06 (0.56, 2.01) 
  Current 67 26 0.63 (0.39, 1.03)  58 13 0.44 (0.23, 0.83) 
 Duration of use, years         
  <5 37 14 0.66 (0.34, 1.25)  31 11 0.70 (0.34, 1.43) 
  ≥5 54 28 0.86 (0.53, 1.41)  49 17 0.68 (0.38, 1.21) 
 Time since first use, years         
  <5 28 8 0.49 (0.22, 1.10)  23 6 0.52 (0.21, 1.29) 
  ≥5 60 31 0.85 (0.53, 1.37)  56 19 0.65 (0.37, 1.13) 
 
Note: CI, confidence interval; OR, odds ratio; PCa, prostate cancer. 
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a Models were adjusted for age (five-year age groups), race (African-American, European-American), 
body mass index (continuous), and history of hypertension (no, yes).   
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Table 4 
Associations between calcium channel blocker use and risk of prostate cancer stratified by 
TMPRSS2:ERG gene fusion status, King County, WA, 1993–1996 and 2002–2005. 
   Calcium channel blocker use 
   No Yes  
   OR (ref) OR (95% CI) 
All men      
  No. controls 1,495 140  
 T2E positive PCa    
  No. cases 286 9  
  Age-adjusted 1.00 0.40 (0.20, 0.79) 
  Multivariable-adjusted
a 1.00 0.38 (0.19, 0.78) 
 T2E negative PCa    
  No. cases 243 25  
  Age-adjusted 1.00 1.11 (0.71, 1.75) 
  Multivariable-adjusted
a 1.00 1.05 (0.65, 1.69) 
      
European-American men    
  No. controls 1,397 124  
 T2E positive PCa    
  No. cases 273 7  
  Age-adjusted 1.00 0.36 (0.16, 0.78) 
  Multivariable-adjusted
a 1.00 0.33 (0.15, 0.73) 
 T2E negative PCa    
  No. cases 219 19  
  Age-adjusted 1.00 1.00 (0.60, 1.66) 
  Multivariable-adjusted
a 1.00 0.99 (0.58, 1.71) 
Note: CI, confidence interval; OR, odds ratio; PCa, prostate cancer; T2E, TMPRSS2:ERG.  
a Models were adjusted for age (five-year age groups), race (African-American, European-American), 
body mass index (continuous), and history of hypertension (no, yes).  
 
 
 
